We would love to hear your thoughts about our site and services, please take our survey here.
Since Avacta technically still owns Coris Concept, worth noting
: Health authorities in Brazil are rushing out limited supplies of a recently approved vaccine as they struggle to contain an unprecedented surge in dengue fever.
Several of Brazil’s most populous states have declared health emergencies in the past month just ahead of carnival season as rising global temperatures and heavy rains brought outbreaks of the tropical disease spread by the Aedes aegypti mosquito.
Brazil has recorded 512 000 dengue cases so far this year—more than three times the number recorded for the same period last year. “We may see the largest number of dengue cases on record this year,
What if :
No placing, but license deal accepted and DX deal in place?
Cash balance looking very strong in front of AACR and further update. Keep hearing AVA3996 quite something , majors at conference would like hear more!
Interesting observation, if one were to compare recent performance of LLY and Novo vs AZN, the weight loss effect on Novo and LLY have resulted in NVO up 70% and LLY up 115% vs AZN - 7% over the last 12 months. So before AACR perhaps the cancer specialist AZN wants to reverse that trend by more M&A in precision oncology sector and look at Avacta Therapeutics for performance.A license deal looks very sensible! They better get a move on, as this year's AACR will be a mega M&A get together.
Lots of fee's to be made. So we should have a license deal with a major very shortly, which will change the rating of Avacta Therapeutics completely.
With hedge funds like Baker brothers stepping up the buying in stocks like Bicycle Therapeutics, pushing the stock 25% up so far in two days , the area looks very interesting as usual and Avacta will look cheaper than ever. A simple read across, makes Avacta Theraprutics during AACR an incredibly well timed IPO , no wonder the excecutives of the " new Avacta Therapeutics " will be residing State side.Sequia will be defending their holding during a very interesting Q2.
Another Biotech transaction:
Larimar Therapeutics, Inc. (NASDAQ:LRMR), a biotech firm specializing in treatments for rare diseases, has initiated an underwritten public offering of its common stock and pre-funded warrants.
On the day of Oppenheim conference.
Pre AACR, the "new Avacta " will very soon be very clear and a complete re- rating of Avacta therapeutics inc. in place.
From market :
Has anyone questioned why London-based #AVCT has recently appointed a full time ‘Head of Research and Development’ based in 🇺🇸?
A role that oversees ‘all clinical development and pre-clinical research activities of the Therapeutics Division’.
Gene editing start-up Metagenomi and cancer specialist NeOnc Technologies have announced the terms of their initial public offerings, in another sign that investor interest in biotech is growing.The company has Moderna, Novo and Bayer among their backers.
This will be of relevance to Avacta's and Daewoong's JV : Affyxell and how the market could remind themselves of the upside in IPO valuation, now with Biocytogen gene editing on board as well.
Will be a great two months before AACR gathering.